Virax Biolabs Reports Positive Early Pilot Data for Long COVID Test, Plans US Market Entry
Summary
Virax Biolabs reported positive early clinical data for its ViraxImmune™ test for Long COVID, demonstrating strong performance metrics and outlining a strategy for U.S. market entry.
Key Events
-
Positive Pilot Data for ViraxImmune™
The blood-based test for Long COVID and related syndromes achieved 88% specificity and 92% positive predictive value in early pilot data, demonstrating measurable separation between PAIS patients and healthy controls.
-
Significant Market Opportunity
The company estimates up to 21 million adults in the U.S. may be living with Long COVID/PAIS, representing a substantial potential U.S. testing opportunity in an area with unmet diagnostic needs.
-
Path to U.S. Market Entry
Virax plans to pursue an initial U.S. Laboratory Developed Test (LDT) route for PAIS, with broader in vitro diagnostic (IVD) development planned over time.
-
Next Clinical Validation Milestone
A larger clinical validation analysis involving 300 additional participants is expected to begin in Q4 2026, with results anticipated in Q1 2027.
Analysis
Virax Biolabs announced encouraging early pilot data for its ViraxImmune™ blood test for Long COVID and related post-acute infection syndromes. The test showed strong specificity and positive predictive value, supporting its potential in a large, underserved market. This positive development is critical for the micro-cap company as it outlines a clear path toward larger clinical validation and a U.S. market entry strategy via a Laboratory Developed Test (LDT) route.
At the time of this filing, VRAX was trading at $0.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.10 to $1.14. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.